It’s of­fi­cial: Bax­alta launches

The Covington News - - BUSINESS - be­come two com­pa­nies in early 2014. Bax­ter In­ter­na­tional is a $9.4 bil­lion med­i­cal prod­ucts com­pany and Bax­alta In­cor­po­rated is a $5.8 Bio­Science busi­ness. Bax­alta is in the process of build­ing a 162 acre fa­cil­ity in Stan­ton Springs In­dus­trial Park off

Bax­alta In­cor­po­rated launched Wed­nes­day as a global bio­phar­ma­ceu­ti­cal com­pany ded­i­cated to de­liv­er­ing trans­for­ma­tive ther­a­pies to pa­tients with or­phan dis­eases and un­der­served con­di­tions.

The com­pany of­fi­cially split off of Bax­ter In­ter­na­tional, which an­nounced the plans to

Bax­alta plans to launch 20 new prod­ucts by 2020, lever­ag­ing the com­pany’s ex­pe­ri­enced lead­er­ship team, ex­ist­ing global ca­pa­bil­i­ties and foot­print in more than 100 coun­tries. As of Wed­nes­day, Bax­alta be­gan trad­ing on the New York Stock Ex­change un­der the ticker sym­bol “BXLT”.

“Bax­alta launches with a rich her­itage in pi­o­neer­ing in­no­va­tions and strate­gic part­ner­ships, which po­si­tions us well to con­tinue to de­velop trans­for­ma­tive ther­a­pies. What sets us apart is our un­com­pro­mis­ing fo­cus on un­der­stand­ing pa­tients’ needs and ex­pe­ri­ences ev­ery step of the way,” said Lud­wig Hantson, chief ex­ec­u­tive of­fi­cer and pres­i­dent, Bax­alta In­cor­po­rated. “We are lever­ag­ing science and ex­ter­nal in­no­va­tion to spark dis­cov­ery and work with all stake­hold­ers – pa­tients, healthcare pro­fes­sion­als and pol­i­cy­mak­ers - to en­sure ac­cess and im­prove stan­dards of care.”

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.